NCT00561275

Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Japanese Foundation for Cancer Research · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1 study of multiple peptide vaccine therapy and GM-CSF in treating patients with esophageal cancer.

Detailed description

LY6K (lymphocyte antigen 6 complex, locus K) was identified as a new target of tumor associated antigen using cDNA microarray technologies combined with the expression profiles of normal and cancer tissues. On the other hand, anti-angiogenic therapy is now considered to be one of promising approaches to treat of cancer. In this clinical trial, we evaluate the safety and immune responses of multiple peptide cocktail including LY6K and vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) together with IFA and GM-CSF as immunoadjuvants in patients who had LY6K expressed primary esophageal cancer. Toxicity profiles will be monitored, and antigen specific T cell responses will be described.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	LY6K, VEGFR1, VEGFR2	1 mg/body every two week with GM-CSF, 4 cycles

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-05-01
• Completion: 2008-06-01
• First posted: 2007-11-20
• Last updated: 2008-07-15

Locations

1 site across 1 country: Japan